Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc.verified

ZNTL

Price:

$13

Market Cap:

$922.48M

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, ...[Read more]

Industry

Biotechnology

IPO Date

2020-04-03

Stock Exchange

NASDAQ

Ticker

ZNTL

The PE Ratio as of April 2024 (TTM) for Zentalis Pharmaceuticals, Inc. (ZNTL) is -2.91

According to Zentalis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.91. This represents a change of -37.98% compared to the average of -4.69 of the last 4 quarters.

Zentalis Pharmaceuticals, Inc. (ZNTL) Historical PE Ratio (quarterly & annually)

How has ZNTL PE Ratio performed in the past?

The mean historical PE Ratio of Zentalis Pharmaceuticals, Inc. over the last ten years is -14.31. The current -2.91 PE Ratio has changed 1.93% with respect to the historical average. Over the past ten years (40 quarters), ZNTL's PE Ratio was at its highest in in the June 2023 quarter at -3.81. The PE Ratio was at its lowest in in the September 2021 quarter at -177.33.

Quarterly (TTM)
Annual

Average

-14.31

Median

-17.96

Minimum

-21.85

Maximum

-3.39

Zentalis Pharmaceuticals, Inc. (ZNTL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Zentalis Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 21.49%

Maximum Annual PE Ratio = -3.39

Minimum Annual Increase = -77.93%

Minimum Annual PE Ratio = -21.85

Quarterly (TTM)
Annual
YearPE RatioChange
2023-3.39-29.65%
2022-4.82-77.93%
2021-21.8521.49%
2020-17.980.19%
2019-17.95-9.75%

Zentalis Pharmaceuticals, Inc. (ZNTL) Average PE Ratio

How has ZNTL PE Ratio performed in the past?

The current PE Ratio of Zentalis Pharmaceuticals, Inc. (ZNTL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-10.02

5-year avg

-13.20

10-year avg

-14.31

Zentalis Pharmaceuticals, Inc. (ZNTL) PE Ratio vs. Peers

How is ZNTL’s PE Ratio compared to its peers?

Zentalis Pharmaceuticals, Inc.’s PE Ratio is greater than Sana Biotechnology, Inc. (-5.56), greater than Olema Pharmaceuticals, Inc. (-5.67), greater than Cullinan Oncology, Inc. (-4.37), less than aTyr Pharma, Inc. (-1.96), greater than Gracell Biotechnologies Inc. (-12.54), greater than Theseus Pharmaceuticals, Inc. (-3.19), less than Monte Rosa Therapeutics, Inc. (-2.35), greater than Design Therapeutics, Inc. (-3.21), less than Erasca, Inc. (-2.30), greater than Day One Biopharmaceuticals, Inc. (-7.38), greater than Inozyme Pharma, Inc. (-3.87), greater than Syndax Pharmaceuticals, Inc. (-7.44), greater than Protagonist Therapeutics, Inc. (-20.96), greater than Revolution Medicines, Inc. (-12.05), greater than Blueprint Medicines Corporation (-10.88), greater than Kymera Therapeutics, Inc. (-14.10), greater than iTeos Therapeutics, Inc. (-3.43), greater than Icosavax, Inc. (-8.27), greater than Mirati Therapeutics, Inc. (-5.32), greater than VectivBio Holding AG (-7.94), less than Annexon, Inc. (-2.71),

Build a custom stock screener for Zentalis Pharmaceuticals, Inc. (ZNTL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zentalis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Zentalis Pharmaceuticals, Inc. (ZNTL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Zentalis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Zentalis Pharmaceuticals, Inc.'s PE Ratio?

How is the PE Ratio calculated for Zentalis Pharmaceuticals, Inc. (ZNTL)?

What is the highest PE Ratio for Zentalis Pharmaceuticals, Inc. (ZNTL)?

What is the 3-year average PE Ratio for Zentalis Pharmaceuticals, Inc. (ZNTL)?

What is the 5-year average PE Ratio for Zentalis Pharmaceuticals, Inc. (ZNTL)?

How does the current PE Ratio for Zentalis Pharmaceuticals, Inc. (ZNTL) compare to its historical average?